The first adult-to-adult living donor liver transplant using the right hepatic lobe in the United States was performed only 2 years ago. Although initial reports were encouraging, continuous review of the results and appropriate modifications in patient management will be necessary to minimize donor risk and optimize recipient outcome. The results of 40 such transplantations were analyzed and are summarized. Recipients were listed for transplantation according to the usual criteria. Living donors were not considered for United Network for Organ Sharing status IIA patients after the initial 22 patients. Donor evaluation followed a rigid protocol. A graft-to-recipient body weight ratio of at least 0.8% was the minimum required throughout most of the study. The surgical procedures were similar, except the plane of transection was modified to better accommodate donor biliary anatomy, and uniform stenting of bile ducts was practiced after the first 10 transplants. Immunosuppression consisted of tacrolimus, mycophenolate mofetil, and a prednisone taper. The target tacrolimus level was decreased and mycophenolate was withdrawn more rapidly in the second half of the study because of the absence of acute cellular rejection. Donor morbidity has been limited to minor complications, and transplant recipient biliary complications decreased from 35% to 0%. Acute cellular rejection has not been observed despite less aggressive immunosuppression, and septic complications decreased dramatically. There have been no recipient deaths since these changes were instituted. Right lobectomy can be performed safely in the donor population. Recipient biliary complications can be minimized with stenting. Less aggressive immunosuppression is well tolerated and minimizes septic complications and attributable mortality. (Liver Transpl 2000;6:296-301.) L iver transplantation has evolved in response to the continued and worsening shortage of organs. Surgical techniques to safely resect viable grafts from living donors have been developed and have the potential to significantly reduce mortality for patients with acute and chronic liver disease. The pediatric population has already realized the benefit of living donors, but progress has been slower for adults. Right lobectomy is the only segmental resection that consistently yields a graft of appropriate size for adults, but it has been approached cautiously because of concern for the safety of the donor. It has only been within the last 2 years that centers in the United States have started to offer this option to their patients. The early reports were encouraging, and enthusiasm has grown as a result. The continued use of this technique must, however, be dependent on a very low incidence of donor complications and demonstrated efficacy in recipients.
L iver transplantation has evolved in response to the continued and worsening shortage of organs. Surgical techniques to safely resect viable grafts from living donors have been developed and have the potential to significantly reduce mortality for patients with acute and chronic liver disease. The pediatric population has already realized the benefit of living donors, but progress has been slower for adults. Right lobectomy is the only segmental resection that consistently yields a graft of appropriate size for adults, but it has been approached cautiously because of concern for the safety of the donor. It has only been within the last 2 years that centers in the United States have started to offer this option to their patients. The early reports were encouraging, and enthusiasm has grown as a result. The continued use of this technique must, however, be dependent on a very low incidence of donor complications and demonstrated efficacy in recipients.
The results of the first 25 adult-to-adult living donor liver transplantations (LDLTs) using the right lobe (RL) performed at our institution were analyzed and previously reported. 1 Only minor complications occurred in donors, and recipient morbidity and mortality were similar to those in cadaveric donor liver transplantation (CDLT). Continuous critical review of the results of these surgeries led to modifications in patient selection, surgical management, and postoperative care, with noticeable improvement in results, particularly with respect to biliary and infectious complications and mortality in transplant recipients. The results of our first 20 RL donor resections and transplants were compared with the results of our second 20 and are summarized here. Changes in management that have led to improved outcome are also highlighted. The results of CDLTs performed during the same interval also serve as a basis for comparison.
Methods
Living donors were considered only after potential transplant recipients were listed for liver transplantation according to the United Network for Organ Sharing (UNOS) criteria. Initially, all patients listed were considered candidates for LDLT, but after the first 22 patients, living donors were no longer evaluated for UNOS status IIA recipients.
A 4-step donor evaluation protocol (Table 1) was rigidly followed in all cases. Briefly, donors were aged between 21 and 55 years, blood group compatible with the intended recipient, free of underlying medical illnesses and cardiovas-cular risk factors, and without evidence of exposure to hepatitis. RL mass was estimated with volumetric magnetic resonance imaging (MRI). For the first 15 donors, an estimated graft-to-recipient body weight ratio (GRBW) of at least 1% was required. Because of overestimation of RL mass by MRI, several livers with a GRBW less than 1% were transplanted. The function of these grafts was essentially identical to those with a GRBW greater than 1%, and the minimum was decreased to 0.8% accordingly. 2 Donors then underwent percutaneous liver biopsy to evaluate the degree of steatosis. The MRI-estimated RL mass was corrected by assuming that each percentage of either microvesicular or macrovesicular fat decreased the functional RL mass by 1%. If the corrected RL mass still gave a GRBW greater than 1% or 0.8%, as previously defined, donors underwent celiac and mesenteric angiography with portal phase, primarily to define the vascular anatomy of segment IV.
A detailed description of the surgical technique has been previously reported. 1 Briefly, intraoperative cholangiography and ultrasonography were performed, followed by cholecystectomy. The vascular structures were identified and isolated, with careful attention to protection of arterial and portal branches to segment IV originating on the right. The midhepatic vein remained with the donor, but accessory hepatic veins greater than 5 mm or determined significant by ultrasonography were preserved and accompanied the graft for later anastomosis to the recipient vena cava. The parenchyma was transected with the aid of the Cavitron Ultrasonic Aspirator (CUSA; Valleylab, Boulder, CO). The plane of transection of the last third of the parenchyma was perfected to include an adequate amount of viable tissue surrounding the bile ducts to the RL. Sharp dissection was used for isolation of the ducts, and their division preceded the transection of the last third of the parenchyma. No inflow control was applied at any point during the hepatectomy. Blood flow to the remnant left lobe was assessed with a Doppler probe before division of the vasculature. After resection, the RL was perfused with University of Wisconsin solution and weighed. The actual corrected GRBW was then calculated.
Recipient surgery consisted of a total hepatectomy with preservation of the inferior vena cava. Venovenous bypass was used in all cases. The donor right hepatic vein was anastomosed to the orifice of the recipient right hepatic vein, and all accessory hepatic veins were anastomosed to the inferior vena cava. Standard portal and arterial reconstructions were possible in most cases. The bile ducts were managed with separate anastomosis to a retrocolic Roux-en-Y limb. Stents were only placed in the first 10 patients if reexploration for a biliary complication became necessary. In the remainder of the patients, the main duct was externally stented with a Turcotte catheter, and minor ducts were internally stented with modified Turcotte catheters. 1 Postoperative immunosuppression for recipients of grafts from living donors consisted of tacrolimus, mycophenolate mofetil (MMF), and a standard prednisone taper. In the first half of the study, a tacrolimus trough level of 10 to 15 ng/mL was considered ideal. In the remainder of the patients, 7 to 10 ng/mL was the target level. MMF was started at 1,000 to 1,500 mg twice daily but was tapered to 250 mg twice daily over the course of 6 months in the first group. In the remainder of the patients, MMF was tapered over the course of 2 months.
Immunosuppression for recipients of cadaveric organs consisted of MMF and prednisone, with initial doses identical to those of living donor transplant recipients. Approximately half the patients were administered cyclosporine, with dosage adjustment for a trough level of 250 to 350 ng/mL, and the other half were administered tacrolimus, with dosage adjustment for a trough level of 8 to 12 ng/mL. MMF was tapered over the course of 6 months in most cadaveric recipients.
Surveillance ultrasonography was routinely performed for the first 3 days postoperatively and after the first week. Thereafter, it was performed only when indicated by the laboratory profile or clinical circumstances. Transplant recipients underwent MRI with simultaneous cholangiography and angiography on postoperative days 7, 14, 30, 60, and 180 to monitor the degree of regeneration and as screening for subclinical complications.
Transplant recipients infected with hepatitis B or C underwent elective liver biopsy 6 months after transplantation, regardless of their clinical status or laboratory profile, and when clinically indicated. In other transplant recipients, biopsy was performed only when clinically indicated. Acute cellular rejection (ACR) was diagnosed histologically according to standardized criteria. No recipient was treated for ACR without tissue diagnosis.
For the purpose of analysis and comparison, donors and recipients of RL grafts were divided into two groups. The first group (A) underwent resection or transplantation between June and December 1998. The second group (B) underwent resection or transplantation after January 1999. The date was chosen to include even numbers in each group while maximizing the distinction between the groups.
Results
From June 1998 through October 1999, a total of 40 LDLTs using the donor RL and 39 whole-organ CDLTs were performed in adult patients at this institution. Living donors were the source of 51% of all organs transplanted. Table 2 lists living donor characteristics, intraoperative data, complications, and overall results. Comparison is made between groups A and B, as defined previously. In 10 pairs in group A, the plane of transection was not modified. The mean follow-up is necessarily shorter for group B, but other characteristics are similar.
Minor complications in donors were limited to intraoperative pressure sores (3 donors), phlebitis (1 donor), prolonged ileus (1 donor), and atelectasis (2 donors), all in group A. There have been no late complications to date. Table 3 lists transplant recipient demographics, intraoperative data, and general results. Table 4 lists significant complications in recipients of grafts from cadaveric and living donors. Both tables compare the results obtained for transplant recipients in groups A and B.
There were no vascular complications or instances of primary nonfunction in transplant recipients in the LDLT group. Portal vein thrombosis occurred in 1 cadaveric transplant recipient, and hepatic artery thrombosis in another. Differences in patient and graft survival between the groups did not achieve statistical significance, but the most recipient deaths clearly occurred in the first group of 20 LDLTs (group A). Four of the five recipients of grafts from living donors who died were UNOS status IIA at transplantation. The immediate cause of death was overwhelming sepsis in all status IIA recipients who died. Vancomycin-resistant Enterococcus was a causative organism in all 4 patients, and Aspergillus organisms were isolated in 3 of the 4 patients, as well. One living donor transplant recipient died of complications associated with multiple myeloma. All grafts were functional at the time of recipient death. Only 1 lost graft was not attributed to the death of the recipient. A large liver infarction secondary to an iatrogenic subcapsular hematoma mandated retransplantation in 1 patient in the second LDLT group. This case has been reported elsewhere. 3 ACR was strikingly less common after LDLT than CDLT. Fewer recipients of grafts from living donors presented with indications for biopsy; therefore, fewer were performed.
Discussion
In our experience, donor complications have fortunately been infrequent and trivial. We attribute this largely to inflexible selection criteria and rigidly controlled surgical management. Decreases in surgical time, incidence of minor complications, need for intensive care unit admission, and length of hospital stay were the only notable changes in the second group of 20 donors. These results are primarily attributable to increasing experience, optimal anesthetic management, and aggressive nursing care. Donor safety has been and must continue to be the primary measure of the success of this technique. Global experience with this technique is still very limited, however. RL LDLT will only have a significant impact if results similar to these can be consistently reproduced at this and other centers. Donor right lobectomy is still in its infancy, and data addressing its safety are relatively scarce. A handful of reports deal specifically with RL resections, but there are significant differences between the surgical techniques. 1, 4 Several centers have reported their experience within a report of greater scope, making it difficult to distinguish what applies to RL donors. 5, 6 Until global experience is more extensive, the statistics from other donor resections and RL resections performed for disease, as well as the personal experience of each surgeon, must be used to arrive at an estimate of risk. Even in the best hands under the best of circumstances, morbidity and mortality will occur. Optimistic but still very realistic estimates are less than 10% and less than 1%, respectively. 1, 7, 8, 9 How much less has yet to be determined. Conscientious review of the results and dissemination of information promises to minimize the number of repeated mistakes and quickly optimize the way these surgeries are performed.
Early in this series, it became obvious that UNOS status IIA patients experienced more complications and had greater mortality than patients who underwent transplantation under more elective circumstances, paralleling the results of CDLTs. 10 We believe the risk for donor complications or death must be offset by benefit to the transplant recipients. We have always weighed the outcome of the donor more heavily and therefore have decided not to offer living donor transplants to UNOS status IIA patients. Our new strategy has been to attack the waiting list from behind with living donors. We see the loss of an organ from a living donor, through either recipient death or graft failure, as more tragic than the loss of a cadaveric organ because of the personal sacrifice involved. Placing these organs into recipients with a good chance of survival minimizes the chance that a graft will be lost. We hope that by increasing the supply of organs with living donors, fewer patients will deteriorate to status IIA, and the overall morbidity and mortality for recipients of all organs, regardless of their source, will improve as a result. 
Analysis of 40 Right-Lobe Liver Transplants
Although only 2 status I patients have received grafts from living donors at this institution, it appears that this group is well served by this technique. One of the 2 patients recovered fully after LDLT. The other was quite recent, and the final outcome has yet to be determined. In this region, the supply of cadaveric organs has become unreliable, and an organ of acceptable quality often cannot be obtained in a timely fashion. The ability to perform transplantation before the onset of irreversible complications or death is frequently the ultimate determinant of survival for status I patients. 11 A full workup can generally be completed in less than 24 hours, and living donors can be called on if an appropriate cadaveric organ does not become available.
Early in this series, biliary complications were quite troublesome and occurred in 35% of the patients. This parallels the initial results of LDLT in the pediatric population. 12, 13 Leakage from the cut surface of the liver, usually manifested by biloma formation, was the most common finding, but stricture and anastomotic leak were also observed. Surgical management was almost universally required. The practice of systemic stenting was initiated early in the series 1 and essentially eliminated early biliary complications. The complication rate in the second group rivals the best reported rate after cadaveric transplantation. 14 The number of patients with multiple ducts was essentially the same in both groups; thus, improved results cannot simply be attributed to less complex reconstruction. Late stricture has not yet occurred in this series, but follow-up is still relatively limited.
ACR has yet to be observed in the adult recipients of grafts from living donors, whereas at least 20% of cadaveric liver transplant recipients experience rejection within the first month. 15 This observation led us to taper MMF more rapidly in the recipients of grafts from living donors and to accept lower tacrolimus levels, as previously described. Rejection has still not occurred despite less aggressive immunosuppression, but the overall incidence of infection and sepsis and their related mortality has declined significantly. The reasons for what seems to be an immunologic advantage in this group of transplant recipients are not entirely clear. Forty percent of the donors were not genetically related to the recipient, and immunologic matching between related individuals was not ideal. Although approximately half the cadaveric transplant recipients were administered cyclosporine instead of tacrolimus, rejection occurred with similar frequency between the 2 groups, paralleling that reported in the literature. 16, 17 It is unlikely that the diagnosis of acute rejection was simply missed in this population because all patients presenting with appropriate indications underwent biopsy, and empiric treatment for ACR was not initiated until tissue was obtained for diagnosis. This phenomenon is currently the subject of investigation.
In summary, modifications in preoperative and postoperative patient management and surgical technique have resulted in less complicated posttransplantation courses and better outcome for recipients of RL grafts from living donors. Ideally, frequent critical review of the results of these procedures will direct the transplant community to protocols and techniques that optimize recipient and graft survival and minimize the risk to living donors. Careful allocation and use of grafts from both cadaveric and living donors promises to decrease overall waiting list and posttransplantation mortality.
